Livzon Pharmaceutical Group (000513.SZ) Earnings Analysis
Livzon Pharmaceutical Group (000513.SZ) next reports earnings on 2026-08-22, consensus EPS 0.64 CNY. Last quarter (2026-04-23) it missed with EPS 0.65 CNY vs 0.72 CNY est (-9.7%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E 13.84.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 000513.SZ next report earnings?
| Next earnings date | 2026-08-22 |
|---|---|
| Consensus EPS estimate | 0.64 CNY |
| Revenue estimate | 2.95B |
000513.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-23 | 0.65 CNY | 0.72 CNY | -9.7% | Miss |
| 2026-03-24 | 0.3 CNY | 0.37 CNY | -18.9% | Miss |
| 2025-10-23 | 0.537 CNY | 0.6 CNY | -10.5% | Miss |
| 2025-04-21 | 0.71 CNY | 0.7 CNY | +1.4% | Beat |
| 2024-08-22 | 0.62 CNY | 0.55 CNY | +12.7% | Beat |
Beat rate: 2/5 (40%) over reported quarters with consensus data.
000513.SZ valuation and analyst view
| Trailing P/E | 13.84 |
|---|---|
| Trailing EPS | 2.212 CNY |
| Price / book | 1.88 |
| Dividend yield | 4.65% |
| Market cap | 27.44B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Livzon Pharmaceutical Group (000513.SZ)'s next earnings date?
Livzon Pharmaceutical Group is next scheduled to report on 2026-08-22, with a consensus EPS estimate of 0.64 CNY and revenue estimate of 2.95B.
Did 000513.SZ beat earnings last quarter?
In its 2026-04-23 report, 000513.SZ posted EPS of 0.65 CNY versus a 0.72 CNY estimate — a miss of 9.7%.
What is 000513.SZ's earnings track record?
Over the last 5 reported quarters with consensus data, 000513.SZ beat estimates 2 times (40%).
What is 000513.SZ's current P/E ratio and EPS?
000513.SZ trades at a trailing P/E of 13.84 on trailing EPS of 2.212208497823165 CNY.
What do analysts rate 000513.SZ?
000513.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.